Boehringer, Zomedica expand point-of-care PPID testing

Zomedica and Boehringer Ingelheim Animal Health USA have launched a strategic collaboration to fold Zomedica’s TRUFORMA point-of-care platform into Boehringer’s idPPID awareness and testing program for horses. The program will use TRUFORMA’s equine endogenous ACTH and insulin assays to support earlier detection and ongoing monitoring of pituitary pars intermedia dysfunction, or PPID. Under the agreement, participating equine practices can receive no-cost TRUFORMA analyzer placement, and Boehringer will reimburse diagnostic testing performed on the platform, alongside existing reimbursement through Cornell University lab testing. (pharmiweb.com)

Why it matters: For equine veterinarians, the collaboration could reduce a longstanding friction point in PPID workups: turnaround time. ACTH testing typically requires careful handling and shipment to an outside lab, while a point-of-care option can speed diagnosis and treatment decisions, especially in horses at risk for laminitis. That matters in a disease Boehringer says is progressive and common in older horses, with Zomedica citing prevalence estimates of roughly 20% to 25% in horses older than 15. Independent research presented in 2025 also found good overall agreement between TRUFORMA’s point-of-care ACTH assay and a chemiluminescent immunoassay reference method, though investigators noted a larger negative bias in PPID horses. (equimanagement.com)

What to watch: Watch for how quickly equine practices enroll, whether reimbursement drives routine screening uptake, and whether more published validation data follow. (pharmiweb.com)